(Q38095989)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Colin F Spraggs

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Christine M Hunt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

541-554

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

Role of tyrosine kinase inhibitors in cancer therapy

28 February 2020

cites work

1 reference

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

21 January 2018

1 reference

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

21 January 2018

1 reference

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.

21 January 2018

1 reference

Immune-mediated adverse drug reactions

21 January 2018

1 reference

Accuracy of hepatic adverse drug reaction reporting in one English health region

21 January 2018

1 reference

Drug-induced liver injury: Hy's rule revisited

21 January 2018

1 reference

Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?

21 January 2018

1 reference

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

21 January 2018

1 reference

The natural history of histologically proved drug induced liver disease

21 January 2018

1 reference

Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

21 January 2018

1 reference

Dasatinib-induced acute hepatitis

21 January 2018

1 reference

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Sorafenib-induced liver failure: a case report and review of the literature

21 January 2018

1 reference

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

Mechanisms of drug-induced liver injury: from bedside to bench

21 January 2018

1 reference

Trastuzumab-induced hepatotoxicity

21 January 2018

1 reference

Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib

21 January 2018

1 reference

Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib

21 January 2018

1 reference

Interaction of lapatinib with cytochrome P450 3A5.

21 January 2018

1 reference

Hepatobiliary transporters and drug-induced cholestasis

21 January 2018

1 reference

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

21 January 2018

1 reference

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

21 January 2018

1 reference

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia

21 January 2018

1 reference

Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels

21 January 2018

1 reference

Genome-wide association of serum bilirubin levels in Korean population

21 January 2018

1 reference

Genome-wide association meta-analysis for total serum bilirubin levels

21 January 2018

1 reference

Case definition and phenotype standardization in drug-induced liver injury.

21 January 2018

1 reference

AGA technical review on the evaluation of liver chemistry tests

21 January 2018

1 reference

A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia.

21 January 2018

1 reference

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

Pharmacogenetics of drug hypersensitivity

21 January 2018

1 reference

Drug-induced liver injury: insights from genetic studies.

21 January 2018

1 reference

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

21 January 2018

1 reference

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome

21 January 2018

1 reference

Iron-overload-related disease in HFE hereditary hemochromatosis

21 January 2018

1 reference

Rechallenge in drug-induced liver injury: the attractive hazard

21 January 2018

1 reference

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer

21 January 2018

1 reference

Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.

21 January 2018

1 reference

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

21 January 2018

1 reference

Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy

21 January 2018

1 reference

MHC class II proteins and disease: a structural perspective

21 January 2018

1 reference

Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex

21 January 2018

1 reference

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

21 January 2018

1 reference

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors

21 January 2018

1 reference

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.13.24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23556451%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference